SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-040106
Filing Date
2024-03-28
Accepted
2024-03-28 08:00:14
Documents
14
Period of Report
2024-03-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm249064d2_8k.htm   iXBRL 8-K 24980
2 EXHIBIT 4.1 tm249064d2_ex4-1.htm EX-4.1 22116
  Complete submission text file 0001104659-24-040106.txt   226503

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA seel-20240327.xsd EX-101.SCH 3015
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE seel-20240327_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE seel-20240327_pre.xml EX-101.PRE 22359
17 EXTRACTED XBRL INSTANCE DOCUMENT tm249064d2_8k_htm.xml XML 3606
Mailing Address 300 PARK AVENUE 2ND FLOOR NEW YORK NY 10022
Business Address 300 PARK AVENUE 2ND FLOOR NEW YORK NY 10022 (646) 293-2100
SEELOS THERAPEUTICS, INC. (Filer) CIK: 0001017491 (see all company filings)

IRS No.: 870449967 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-22245 | Film No.: 24793595
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)